[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Bristol-Myers Squibb Stock Rises on Anthropic AI Deal. Why This Could Actually Be a Key Upside Catalyst.

Bristol-Myers Squibb (BMY) just handed investors a compelling new reason to pay attention to BMY stock, and it could matter more than the market is giving it credit for. The pharmaceutical giant's new artificial intelligence (AI) partnership with Anthropic could be a key catalyst, not just a headline — and when you layer it on top of the company's already strong pipeline momentum, the case for owning this blue-chip stock into 2030 gets a lot more interesting.

Let's take a closer look.

Fundamentals

See More
  • Market Capitalization, $K 121,605,328
  • Shares Outstanding, K 2,042,071
  • Annual Sales, $ 48,194 M
  • Annual Income, $ 7,054 M
  • EBIT $ 12,521 M
  • EBITDA $ 16,532 M
  • 60-Month Beta 0.26
  • Price/Sales 2.48
  • Price/Cash Flow 7.20
  • Price/Book 5.95

Options Overview Details

View History
  • Implied Volatility 26.51% (+0.09%)
  • Historical Volatility 24.69%
  • IV Percentile 17%
  • IV Rank 29.39%
  • IV High 40.88% on 11/19/25
  • IV Low 20.52% on 12/31/25
  • Expected Move (DTE 7) 1.40 (2.36%)
  • Put/Call Vol Ratio 1.25
  • Today's Volume 28,524
  • Volume Avg (30-Day) 23,511
  • Put/Call OI Ratio 0.85
  • Today's Open Interest 621,690
  • Open Int (30-Day) 583,692
  • Expected Range 58.06 to 60.86

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 31 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.63
  • Number of Estimates 11
  • High Estimate $1.71
  • Low Estimate $1.55
  • Prior Year $1.46
  • Growth Rate Est. (year over year) +11.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
55.40 +7.32%
on 05/11/26
60.78 -2.17%
on 04/30/26
+0.66 (+1.12%)
since 04/22/26
3-Month
55.40 +7.32%
on 05/11/26
62.89 -5.45%
on 03/02/26
-1.20 (-1.98%)
since 02/20/26
52-Week
42.52 +39.84%
on 10/29/25
62.89 -5.45%
on 03/02/26
+12.43 (+26.43%)
since 05/22/25

Most Recent Stories

More News
Bristol-Myers Squibb Stock Rises on Anthropic AI Deal. Why This Could Actually Be a Key Upside Catalyst.

BMY stock rose after the company announced a strategic AI deal with Anthropic to deploy Claude across its workforce.

BMY : 59.46 (-0.15%)
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline

Late-breaking Phase 3 SUCCESSOR-2 study results highlight potential of mezigdomide, a novel CELMoD from the Company’s targeted protein degradation platform, in relapsed or refractory multiple myeloma...

BMY : 59.46 (-0.15%)
1 Profitable Stock to Keep an Eye On and 2 We Brush Off

1 Profitable Stock to Keep an Eye On and 2 We Brush Off

MC : 65.76 (+0.17%)
KMI : 33.79 (+0.87%)
BMY : 59.46 (-0.15%)
Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations

The collaboration brings together BMS’ deep scientific expertise and Anthropic's frontier AI to accelerate the discovery, development and delivery of transformational medicines ...

BMY : 59.46 (-0.15%)
Supreme Court Rejects Drugmakers’ Challenge to Medicare Price Negotiation Program

The U.S. Supreme Court on Monday declined to hear a pharmaceutical industry challenge to the Medicare drug price negotiation program created under the Inflation Reduction Act, leaving in place lower court...

NVO : 44.96 (+1.28%)
JNJ : 234.34 (+1.13%)
BMY : 59.46 (-0.15%)
Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new initiative with Bristol Myers Squibb (NYSE: BMY). This collaboration...

TEM : 46.18 (-0.67%)
BMY : 59.46 (-0.15%)
2 Large-Cap Stocks to Consider Right Now and 1 We Turn Down

2 Large-Cap Stocks to Consider Right Now and 1 We Turn Down

BSX : 57.78 (+1.10%)
HPE : 37.58 (+10.63%)
BMY : 59.46 (-0.15%)
Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees

Highlights Nominees’ Robust Skillsets and Extensive Experience in Healthcare and Biopharmaceuticals Urges Stockholders to Vote “ FOR ” the Election of Pacira’s Highly Qualified Nominees...

PCRX : 23.35 (-0.55%)
BMY : 59.46 (-0.15%)
Bristol-Myers Squibb (BMY): Buy, Sell, or Hold Post Q1 Earnings?

Bristol-Myers Squibb (BMY): Buy, Sell, or Hold Post Q1 Earnings?

BMY : 59.46 (-0.15%)
Bristol Myers Squibb Touts Pipeline Gains as Shareholders Back Board at Annual Meeting

Bristol Myers Squibb (NYSE:BMY) used its 2026 annual meeting of shareholders to highlight progress in its growth portfolio, pipeline development, balance sheet management and cost-saving initiatives, while...

BMY : 59.46 (-0.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers...

See More

Key Turning Points

3rd Resistance Point 61.06
2nd Resistance Point 60.65
1st Resistance Point 60.06
Last Price 59.46
1st Support Level 59.06
2nd Support Level 58.65
3rd Support Level 58.06

See More

52-Week High 62.89
Last Price 59.46
Fibonacci 61.8% 55.11
Fibonacci 50% 52.70
Fibonacci 38.2% 50.30
52-Week Low 42.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.